State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, China.
Department of Hepatobiliary Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
Cancer Commun (Lond). 2018 May 21;38(1):26. doi: 10.1186/s40880-018-0296-x.
Average postoperative follow-up intervals vary in patients undergoing hepatocellular carcinoma (HCC) resection because of limited evidence regarding the optimal interval. We aimed to compare the associations of long-versus short-interval follow-up with survival and recurrence in risk-stratified HCC patients.
We performed a retrospective cohort study between 2007 and 2014. In total, 1227 patients treated by curative resection of Barcelona Clinic Liver Cancer stage A or B HCC were stratified as having a low (n = 865) or high (n = 362) risk of early recurrence (within the first 2 years after resection) based on prognostic factors identified by the least absolute shrinkage and selection operation algorithm. Patients were further classified into long-interval (every 4-6 months) and short-interval (every 2-4 months) follow-up subgroups based on follow-up within 2 years after resection (low risk, long vs. short: n = 390 vs. n = 475; high-risk, long vs. short: n = 149 vs. n = 213).
The short-interval follow-up did not prolong overall survival in either the low-risk (hazard ratio [HR] = 1.152; 95% confidence interval [CI] 0.720-1.843) or high-risk (HR = 1.213; 95% CI 0.702-2.094) patients. Early recurrence occurred in 401 patients. For high-risk patients, the short-interval follow-up subgroup exhibited smaller intrahepatic recurrence than did the long-interval group (2.6 vs. 3.5 cm, respectively, P = 0.045). However, no significant difference in the rate of Barcelona Clinic Liver Cancer stage 0/A recurrence was found between the long- and short-interval follow-up groups in either low- or high-risk patients (63.1% vs. 68.2%, respectively, P = 0.580; 31.3% vs. 41.5%, respectively, P = 0.280). The rate of curative intent treatment for recurrence (34.5% vs. 39.7%, respectively, P = 0.430; 14.6% vs. 20.3%, respectively, P = 0.388) was also similar between the follow-up groups for low- and high-risk patients.
Shortening the postoperative follow-up interval from every 4-6 months to every 2-4 months within the first 2 years after resection did not increase the rate of curative intent treatment or prolong the overall survival of patients with Barcelona Clinic Liver Cancer stage A or B HCC.
由于缺乏关于最佳间隔时间的证据,行肝细胞癌(HCC)切除术的患者术后随访间隔时间各不相同。我们旨在比较长间隔与短间隔随访与风险分层 HCC 患者生存和复发的关系。
我们在 2007 年至 2014 年期间进行了一项回顾性队列研究。总共对 1227 例接受巴塞罗那临床肝癌分期 A 或 B HCC 根治性切除术的患者进行了分层,根据预后因素(最小绝对收缩和选择操作算法确定),将低风险(n=865)或高风险(n=362)早期复发(术后 2 年内)患者分为低风险(低风险:长间隔 vs. 短间隔:n=390 vs. n=475)和高风险(高风险:长间隔 vs. 短间隔:n=149 vs. n=213)。
在低风险(风险比[HR] = 1.152;95%置信区间[CI] 0.720-1.843)或高风险(HR = 1.213;95%CI 0.702-2.094)患者中,短间隔随访并未延长总体生存。401 例患者发生早期复发。对于高危患者,短间隔随访组的肝内复发率小于长间隔组(分别为 2.6 cm 和 3.5 cm,P=0.045)。然而,在低危或高危患者中,长间隔和短间隔随访组的巴塞罗那临床肝癌分期 0/A 复发率均无显著差异(分别为 63.1%和 68.2%,P=0.580;分别为 31.3%和 41.5%,P=0.280)。对于低危和高危患者,复发后进行根治性治疗的比例(分别为 34.5%和 39.7%,P=0.430;分别为 14.6%和 20.3%,P=0.388)在两组随访中也相似。
在术后 2 年内,将随访间隔从每 4-6 个月缩短至每 2-4 个月,并未增加接受巴塞罗那临床肝癌分期 A 或 B HCC 患者的根治性治疗率或延长总体生存率。